Expert Interviews

Petros Grivas, MD, PhD; Guru P. Sonpavde, MD; Thomas Powles, MBBS, MRCP, MD; and Neeraj Agarwal, MD, share their approach to frontline therapy for patients with advanced urothelial carcinoma and consider the impact of cisplatin eligibility.

Sara A. Hurvitz, MD, and Steven E. Vogl, MD, discuss clinical implications of a recently published review of third-line therapy options for patients with HER2-positive metastatic breast cancer.

Neil Iyengar, MD; Claudine Isaacs, MD; Virginia Kaklamani, MD; and Vijayakrishna Gadi, MD, PhD, share clinical pearls for the evolving treatment landscape of HER+ metastatic breast cancer.

Bladder cancer experts discuss the importance of detecting early signs and symptoms leading to the diagnosis of advanced urothelial cancer.

Sara A. Hurvitz, MD, and Steven E. Vogl, MD, highlight key concepts from a recently published review of third-line therapy options for patients with HER2-positive metastatic breast cancer.

Vijayakrishna Gadi, MD, PhD, presents the case of a 63-year-old woman with grade 3 HER+/HR- metastatic breast cancer.

Neeraj Agarwal, MD, leads the discussion on the typical patient presentation and major risk factors for urothelial cancer.

CancerNetwork® sat down with Sara A. Hurvitz, MD, at the 2021 ASCO Annual Meeting to talk about multidisciplinary care with geriatrician oncologists and the use of age-based analyses for diagnosis and following up of metastatic triple-negative breast cancer.

CancerNetwork® sat down with Sylvie Bonvalot, MD, PhD, at the 2021 ASCO Annual Meeting to talk about treatment options for high-grade or grade II sarcoma.

Breast cancer experts discuss the importance of patient quality of life when considering treatment recommendations for HER2+ breast cancer.

Claudine Isaacs, MD, comments on the follow-up and monitoring for a patient similar to the case presentation with HER2+ breast cancer.

CancerNetwork® sat down with Funda Meric-Bernstam, MD, at the 2021 ASCO Annual Meeting to talk about results of the MyPathway study in HER2-positive advanced solid tumors treated with pertuzumab plus trastuzumab.

Eytan Stein, MD, considers promising, new therapeutic options for adult patients with acute myeloid leukemia.

Dr Stein elaborates on some practical considerations for the use of venetoclax and hypomethylating agents for the treatment of patients with chemotherapy-ineligible acute myeloid leukemia.

An expert lists the information physicians consider when choosing a first-line therapy for patients with chemotherapy-ineligible acute myeloid leukemia.

Eytan Stein, MD, discusses the predictive and prognostic factors for patients with chemotherapy-ineligible acute myeloid leukemia.

An expert explains the first-line treatment options for patients with chemotherapy-ineligible acute myeloid leukemia.

Dr Stein elaborates on the impact of the approval of small molecule inhibitors for the treatment of acute myeloid leukemia.

Eytan Stein, MD, discusses the therapeutic standards of care for newly diagnosed adult patients with acute myeloid leukemia.

CancerNetwork® sat down with Jorge Nieva, MD, at the 2021 ASCO Annual Meeting to talk about the future of clinical trials for early-stage non–small cell lung cancer.